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3-M syndrome is a rare autosomal recessive disorder that causes short stature, unusual facial features and skeletal
abnormalities. Mutations in the CUL7, OBSL1 and CCDC8 genes could be responsible for 3-M syndrome.
Here we describe the growth and evolution of dismorphic features of an Italian boy with 3-M syndrome and
growth hormone deficiency (GHD) from birth until adulthood. He was born full term with a very low birth weight
(2400 g=−3.36 standard deviation score, SDS) and length (40.0 cm =−6.53 SDS). At birth he presented with a broad,
fleshy nose with anteverted nostrils, thick and patulous lips, a square chin, curvilinear shaped eyebrows without
synophrys, short thorax and long slender bones. Then, during childhood tall vertebral bodies, hip dislocation,
transverse chest groove, winged scapulae and hyperextensible joints became more evident and the diagnosis of
3-M syndrome was made; this was also confirmed by the finding of a homozygous deletion in exon 18 of the CUL7
gene, which has not been previously described.
The patient also exhibited severe GHD (GH <5 ng/ml) and from the age of 18 months was treated with rhGH.
Notwithstanding the early start of therapy and good compliance, his growth rate was always very low, except for
the first two years of treatment and he achieved a final height of 132 cm (−6.42 SDS).
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3-M syndrome (OMIM273750) is a rare autosomal re-
cessive disorder that causes short stature, unusual facial
features and skeletal abnormalities [1]. The name of
this condition comes from the initials of the three re-
searchers (Miller, McKusik and Malvaux) who first
identified it. Individuals affected by 3-M syndrome have
intrauterine growth retardation (IUGR) and postnatal
growth retardation, worsened also by feeding difficulties
during the first years of life. Affected patients usually
have a triangle-shaped face with a pointed chin, large
ears, full eyebrows, an upturned nose with a fleshy tip,
long philtrum, and a prominent mouth with full lips.
They may also exhibit prominent shoulder blades and
square shoulders, exaggerated curvature of the lower
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reproduction in any medium, provided the orprominent heels and other skeletal abnormalities which
are apparent in X-ray images [2].
Mutations in the CUL7 gene cause 3-M syndrome, al-
though genetic heterogeneity has been reported [3,4] in-
volving two other causative genes, OBSL1 and CCDC8
[5-7]. Since CUL7 is involved in chondrocyte growth
and proliferation, in 3-M syndrome, reduced cell mitosis
during the early gestation period could be the cause of
retarded growth. In particular, these mutations disrupt
the ability of the protein cullin-7 to bring together the
components of the ubiquitine-proteasome system which
is involved in the degradation of unwanted proteins.
Therefore, impaired ubiquitination may have a role in
the pathogenesis of IUGR in humans.
Here, we describe a patient with 3-M syndrome and
GH deficiency, who was followed from the age of two
years to adulthood. Even though rhGH therapy was
started early in infancy (18 months of age) with good
compliance, no catch-up growth was observed.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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An Italian boy born after 42 weeks gestation compli-
cated by partial detachment of the placenta was evalu-
ated at our institute from the age of two months. Birth
length was 40.0 cm (−6.53 standard deviation score,
SDS) and birth weight was 2,400 g (−3.36 SDS). His tar-
get height was 165 cm (−1.28 SDS). At two months he
showed some dismorphic features: broad and fleshy nose
with anteverted nostrils, thick and patulous lips, square
chin, curvilinear shaped eyebrows without synophrys,
short thorax, distended abdomen, flat feet, long slender
bones and ribs which contrasted with the child’s stocky
appearance (Figure 1a and 1b). Only at 3 years did the
patient exhibit a large head circumference (the head was
disproportionately large in comparison with the body),
prominent forehead, anteverted nares, round face,
frontal bossing and short broad neck with prominent
trapezius muscles, tall vertebral bodies, and hip disloca-
tion (Figure 1c). From the age of 7–8 years triangular-
shaped face, frontal bossing, transverse chest groove,
winged scapulae and hyperextensible joints became very
evident (Figures 1a and 2b and Figure 3). Since radio-
logical findings suggested hypochondroplasia, a first
genetic analysis of exon 13 of the FGFR-3 gene was
performed. However, no mutations associated with
hypochondroplasia were found. Finally, the diagnosis of
3-M syndrome was made, confirmed by the analysis of
the CUL7 gene. In fact, an homozygous deletion of the
10 bp TTGGCTACCC (c.3388_3397del10) in exon 18
of the CUL7 gene was found. This variation found is
not an annotated SNP and has not been previously
described. The deletion predicts a frameshift and aFigure 1 The patient at one (a), two (b) and three (c) years of age wit
relatively increased head circumference, triangular face, hypoplastic m
nose, long philtrum, full lips, and pointed, prominent chin.preterminal stop codon (p.Leu1130GlyfsX8) resulting in
a truncated cullin 7 protein. The homozygous 10 bp de-
letion is, therefore, very likely the cause of the patient’s
type 1 3-M syndrome. His parents, his younger brother
and his older sister are all unaffected heterozygous car-
riers of the deletion. The sister is healthy, without
dismorphic features and a final height around the 10th
percentile. On the contrary, the brother shows some fa-
cial dismorphisms, a psychomotor delay and cardio-
logical defects, not related to 3-M syndrome.
At the age of 18 months he underwent an endocrino-
logical evaluation since his height was 64 cm (−6.57
SDS) and bone age was less than 12 months; a diagnosis
of growth hormone deficiency (GHD) was made (GH
peak after arginine: 0.93 ng/ml; GH peak after glucagon:
4.19 ng/ml; cut-off 10 ng/ml). Thyroid and cortisol func-
tions were normal. Celiac disease was also excluded.
rhGH therapy was started at the dose of 0.25 mg/kg/
week and his height was measured every six months
(Figure 4); after the first year of treatment the growth
rate was 10.1 cm (1.63 SDS) and after the second year
it was 6 cm (−0.27 SDS). At the age of 7.1 years, his
growth failure became more evident (height 94.3 cm=
−4.52 SDS, bone age of 5 years, growth rate 1.4 cm/
year=−4.46 SDS) and rhGH therapy was discontinued.
After some months, GH secretion was re-evaluated and
partial GHD was confirmed (GH peak after arginine:
4.0 ng/ml; GH peak after glucagon: 7.15 ng/ml), there-
fore rhGH therapy was restarted until the patient was
14.3 years-old, when it was definitively interrupted. His
height was 122.5 cm (−4.25 SDS) with a growth rate of
4.2 cm/year (−0.42 SDS). His bone age was 12.5 years.h typical 3-M syndrome facial features including frontal bossing,
idface, low nasal bridge, depressed nasal root, fleshy upturned
Figure 2 Patient at 15 (a) and 17.5 (b) years showing facial dismorphism, short stature, broad thorax, sternum carinatum.
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showed an increase from −0.5 SDS to 0.5 SDS and GH
secretion after arginine was 17.3 ng/ml. His final stature
at 18 years is 132 cm (−6.42 SDS).
We observed a slight delay in pubertal development;
at the age of 13.8 years he showed reduced luteinizing
hormone (LH) levels (2.0 IU/L; normal values
6–30 IU/L) and a gonadal volume of about 6 ml. How-
ever, at 18 years his gonadal volume was within the
normal range (15–20 ml).
Discussion
3-M dwarfism is a clinical entity which is not often rec-
ognized in childhood. Here, we describe a patient with
3-M syndrome associated with GHD. The child was very
small at birth and severe growth restriction continued in
the post-natal period and throughout childhood. In fact,
his final stature is −6.42 SDS. In our patient, skeletal
changes typical of 3-M syndrome, such as long slender
bones, tall vertebral bodies, triangular-shaped face with
square chin, short thorax, transverse chest groove and
winged scapulae were not present at birth, but
manifested in the course of childhood. Therefore, thediagnosis of 3-M syndrome was made only when the
patient was 17 year-old, after having investigated other
potential syndromes such as hypocondroplasia. How-
ever, an early diagnosis is important for familial genetic
familiar counselling since 3-M syndrome has an auto-
somal recessive mode of inheritance. It is important to
closely follow patients with syndromic features and per-
form genetic analyses as the dismorphic features be-
come apparent.
3-M dwarfism belongs to a group of intrauterine
growth retardation-malformation syndromes. There-
fore, differentiation from Russell-Silver syndrome is dif-
ficult because of the phenotypic variability of the latter.
Body asymmetry is not present in 3-M syndrome, while
short stature with prenatal onset and a small triangular
face are found in both syndromes. However, 3-M sub-
jects are shorter than those with Russell-Silver syn-
drome [8,9].
The most striking feature of 3-M syndrome is severe
growth retardation. According to other cases reported
in the literature, the present patient achieved a height
between 4 and 6 SD below the mean [10]. Since our
patient also exhibited severe GHD, rhGH therapy was
Figure 3 Radiographic features of the adult 3-M syndrome patient. On the lateral lumbar spinal radiograph (left panel), vertebral bodies are
relatively tall and short. Lumbar hyperlordosis is caused by the short femoral necks. In the central panel, note the short femoral necks with
anterior rotation of the pelvis (small foramina obturatoria). The ribs and the visible part of the femoral shafts are slender. The distance between
the vertebral pedicles remains constant from L1 to L5. The tibia and fibula (right panel) are relatively inconspicuous. The radiographic features
fitting with the diagnosis of 3-M are the tall and narrow vertebral bodies and slender tubular bones; other features of a chondrodysplasia, such as
platyspondily or metaphyseal and epiphyseal changes, are typically absent.
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case of partial GH deficiency in a 3-M syndrome pa-
tient has been described [1]. However, in the six cases
described by van der Wal et al. [10], five patients were
treated with rhGH independently from normal GH se-
cretion, but only the two patients who started GH
treatment at a prepubertal stage showed a good re-
sponse and their adult height was well above the final
height of the other three cases. On the other hand,
Russell-Silver syndrome patients benefit from GH sup-
plementation even in the absence of GHD [11] and
show significant growth acceleration and improved
final height, even when GH therapy is initiated later in
life [12]. In our patient, even though rhGH therapy
was started early in infancy (18 months of age) with
good compliance, no catch-up growth was observed.
His slow growth continued throughout childhood and
adolescence leading to a final height of 132 cm, well
below his target height. Our patient’s blunted response
to rhGH therapy may be due to the presence of the
mutation in the CUL7 gene which may strongly affect
GH effects on longitudinal growth. In fact, it has been
reported that subjects with CUL7 mutations are sig-
nificantly shorter than those with OBSL1 or CCDC8
mutations [7].Finally, we observed a rather normal sexual develop-
ment confirming that male gonadal dysfunction is not a
concomitant feature of 3-M syndrome, as also reported
in previous studies [1].
In conclusion, there are many typical features of 3-M
syndrome, but, apart from a very severe growth retard-
ation, patients may not exhibit these from birth. Many
other syndromes with short stature should be considered
when making a differential diagnosis of 3-M syndrome,
i.e. Silver-Russel syndrome, Bloom syndrome, Dubowitz
syndrome, Rubistein-Taybi syndrome, Floating-Harbor
syndrome, Mulibrey nanism and fetal alcohol syndrome,
but the most difficult to differentiate is Silver-Russel syn-
drome. However, during childhood, subjects with 3-M
syndrome develop striking radiological abnormalities,
making the diagnosis possible. Finally, the diagnosis
should be confirmed by the presence of mutations in the
CUL7 gene, which account for about 80% of 3-M syn-
drome patients [4].
Consent
Written informed consent was obtained from patient’s
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Figure 4 Growth chart for height of the patient from birth until adult age. TH=target height.
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